BU-NOT-SET
- Recipharm completes the sale of its Yavne, Israel, API development and manufacturing site to Scinai Immunotherapeutics Ltd.
- Long-term strategic commercial collaboration established to support seamless programme progression from early development to commercial supply within Recipharm’s global network.
- Recipharm continues to offer broad early-stage development and clinical manufacturing capabilities for biologic molecules and for drug product development across its global CDMO network, with the collaboration further enhancing its integrated development-to-commercialisation pathway.
Recipharm, a leading global contract development and manufacturing organisation (CDMO), today announced the completion of the sale of its Yavne, Israel manufacturing site to Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI; "Scinai"), alongside the establishment of a long-term strategic commercial collaboration between the two companies.
The transaction reflects Recipharm's continued focus on optimising its global manufacturing network while building strategic partnerships that enhance its early-stage pipeline access and long-term commercial opportunities.
Under the terms of the agreement, Recipharm has transferred ownership of Recipharm Israel Ltd., its cGMP API development and small-scale manufacturing facility in Yavne, Israel, to Scinai. The transaction was structured to ensure full operational continuity, including employees and existing customer programmes.
The Yavne site provides early chemistry development and small-scale API manufacturing services supporting clinical stage programmes. As part of Scinai's CDMO platform, the facility will continue serving customers without disruption.
Concurrently, Recipharm and Scinai have entered into a Commercial Collaboration Agreement designed to create seamless development to commercialisation pathway for clients. Under the agreement:
- Recipharm will serve as one of Scinai's preferred partners for late-stage clinical and commercial manufacturing, subject to capacity and technical fit;
- Scinai will act as preferred-early stage development partner within Recipharm's ecosystem
- The companies will establish pre-aligned quality and tech transfer frameworks to enable efficient programme transitions
- Scinai may subcontract selected manufacturing and development capabilities from Recipharm under an agreed commercial framework, enabling integrated service delivery across both organisations;
- The parties will mutually refer projects.
Greg Behar, CEO of Recipharm, said: "This transaction reflects our ongoing efforts to actively manage and strengthen Recipharm's global network while ensuring continuity for employees and customers at the Yavne site. Recipharm continues to offer broad early-stage development and clinical manufacturing capabilities for biologic molecules and for drug product development across our CDMO platform. Through our collaboration with Scinai, we are adding an additional, high-quality pathway whose programmes originate in Israel to progress efficiently into late-stage and commercial supply within Recipharm's global network, supported by aligned quality and tech transfers frameworks."
"This transaction fundamentally strengthens Scinai's CDMO platform," said Amir Reichman, Chief Executive Officer of Scinai. "By combining our early-stage development strengths with Recipharm Israel's manufacturing capabilities and Recipharm's global footprint, we are creating a differentiated offering that supports clients from early development through commercialization. Importantly, the collaboration allows Scinai to participate in the long-term success of client programs while maintaining capital discipline and operational focus."
Ends)
For more information
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company with two complementary business units:
- Scinai Bioservices, a boutique CDMO providing analytical method development, process development, and clinical cGMP manufacturing services for biotech clients worldwide.
- Scinai R&D, focused on developing innovative inflammation and immunology therapeutics based on NanoAbs (VHH antibody fragments) with unique physicochemical properties suitable for advanced mono- and multi-specific antibody formats.
Company website: www.scinai.com
About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) employing over 5,000 employees worldwide. Recipharm provides manufacturing services of pharmaceuticals in various dosage forms, including sterile fill & finish, oral solid dosage and biologics; clinical trial material development and manufacturing services; and pharmaceutical product development. Its Recipharm Advanced Bio segment works with customers to develop and commercialise advanced therapy medicinal products (ATMPs): pre-clinical to clinical development, commercial development and manufacture for new biological modalities, encompassing technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production.
Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. It operates development and manufacturing facilities in France, Germany, India, Italy, Portugal, Spain, Sweden and the US.
For more information about Recipharm, please visit www.recipharm.com and www.recipharm-ab.com
Media contact:
Guenaelle Holloway, Head of communications
[email protected]
+44 7730 303 708